Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 18/20 | 0.83 |
| ▸ | GNRHR | P30968 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29635486 | 0.86 | CXCR4 (0.73) | CXCR4GNRHR | |
| SCHEMBL29350127 | 0.82 | NTSR2 (0.63) | CXCR4GNRHR | |
| SCHEMBL29437878 | 0.82 | CXCR4 (0.91) | CXCR4 | |
| SCHEMBL29491173 | 0.82 | C5AR1 (0.65) | CXCR4GNRHR | |
| SCHEMBL31088157 | 0.82 | GNRHR (0.83) | CXCR4GNRHR | |
| SCHEMBL29497292 | 0.81 | AGTR2 (0.67) | CXCR4GNRHR | |
| SCHEMBL29914749 | 0.80 | GNRHR (0.85) | CXCR4GNRHR | |
| SCHEMBL29716634 | 0.80 | NTSR2 (0.75) | CXCR4GNRHR | |
| SCHEMBL30893565 | 0.80 | CXCR4 (0.63) | CXCR4 | |
| SCHEMBL29373933 | 0.79 | PTGS1 (0.72) | CXCR4GNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428456-B2 | Peptide directed protein knockdown | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-09-30 | — | — | US | disclosed |
| EP-3962491-B1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | UNIV SANTIAGO COMPOSTELA (ES) | 2025-08-06 | — | — | EP | disclosed |
| US-11590198-B2 | Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells | UNIVERSITAT AUTONOMA DE BARCELONA (ES) | 2023-02-28 | — | — | US | disclosed |
| CN-113069555-B | Bispecific glycopeptide nano molecule and preparation method and application thereof | 国家纳米科学中心 | 2022-09-06 | — | — | CN | disclosed |
| US-20220177603-A1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-06-09 | — | — | US | disclosed |
| EP-3962491-A1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | Universidade De Santiago De Compostela (ES) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177603-A1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | KRAS, NRAS, TP53 | CXCR4 2606/4885GNRHR 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.